{"id":"sb206-12","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2109480","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SB206 is a proprietary formulation that releases nitric oxide, a signaling molecule with antimicrobial and wound-healing properties. Nitric oxide has been shown to have broad-spectrum antimicrobial activity and can enhance tissue repair processes. The 12% formulation is designed for topical application to treat dermatological conditions.","oneSentence":"SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:34.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Molluscum contagiosum"},{"name":"Warts"}]},"trialDetails":[{"nctId":"NCT03436615","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2018-01-24","conditions":"Molluscum Contagiosum","enrollment":256},{"nctId":"NCT03927703","phase":"PHASE3","title":"A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2019-06-13","conditions":"Molluscum Contagiosum","enrollment":355},{"nctId":"NCT04535531","phase":"PHASE3","title":"A Phase 3 Molluscum Contagiosum Efficacy and Safety Study","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2020-09-01","conditions":"Molluscum Contagiosum","enrollment":891},{"nctId":"NCT03927716","phase":"PHASE3","title":"A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2019-06-03","conditions":"Molluscum Contagiosum","enrollment":352}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["berdazimer sodium","NVN1000"],"phase":"phase_3","status":"active","brandName":"SB206 12%","genericName":"SB206 12%","companyName":"Novan, Inc.","companyId":"novan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB206 is a nitric oxide-releasing topical agent that delivers nitric oxide to skin lesions to promote healing and reduce bacterial burden. Used for Molluscum contagiosum, Warts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}